Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

X4 Pharmaceuticals (XFOR) Net Income towards Common Stockholders (2018 - 2025)

Historic Net Income towards Common Stockholders for X4 Pharmaceuticals (XFOR) over the last 8 years, with Q3 2025 value amounting to -$29.8 million.

  • X4 Pharmaceuticals' Net Income towards Common Stockholders rose 1875.14% to -$29.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$95.1 million, marking a year-over-year decrease of 46742.65%. This contributed to the annual value of -$37.5 million for FY2024, which is 6293.26% up from last year.
  • As of Q3 2025, X4 Pharmaceuticals' Net Income towards Common Stockholders stood at -$29.8 million, which was up 1875.14% from -$25.7 million recorded in Q2 2025.
  • Over the past 5 years, X4 Pharmaceuticals' Net Income towards Common Stockholders peaked at $90.8 million during Q2 2024, and registered a low of -$55.7 million during Q2 2023.
  • Its 5-year average for Net Income towards Common Stockholders is -$20.7 million, with a median of -$24.2 million in 2022.
  • Within the past 5 years, the most significant YoY rise in X4 Pharmaceuticals' Net Income towards Common Stockholders was 26304.03% (2024), while the steepest drop was 149201.74% (2024).
  • Over the past 5 years, X4 Pharmaceuticals' Net Income towards Common Stockholders (Quarter) stood at -$35.9 million in 2021, then grew by 18.96% to -$29.1 million in 2022, then surged by 34.27% to -$19.1 million in 2023, then crashed by 108.16% to -$39.8 million in 2024, then increased by 25.13% to -$29.8 million in 2025.
  • Its last three reported values are -$29.8 million in Q3 2025, -$25.7 million for Q2 2025, and $282000.0 during Q1 2025.